1.2. High-dose IV acyclovir decreases mortality and improves neurologic outcomes among survivors of neonatal HSV disease. • Six months of suppressive therapy with oral acyclovir after completion of parenteral therapy in acute disease further improves neurologic outcomes
1.3. Duration of treatment :skin and mouth disase…14 days
1.4. women with active primary genital lesions should be treated with preemptive parenteral acyclovir for… 10 days
1.5. CNS…21 days
1.6. Foscarnet (Foscavir) • Foscarnet is the drug of choice to treat acyclovir resistant strains of HSV, varicella zoster virus (VZV), and CMV. • Foscarnet is an inorganic pyrophosphate analogue that directly inhibits DNA polymerase
1.7. Foscarnet (Foscavir) • Foscarnet is the drug of choice to treat acyclovir resistant strains of HSV, varicella zoster virus (VZV), and CMV. • Foscarnet is an inorganic pyrophosphate analogue that directly inhibits DNA polymerase
2. Neuraminidase Inhibitors
2.1. Oseltamivir (Tamiflu) prophylaxis of influenza in children less than 5 years of age. • The main side effect includes gastrointestinal complaints. • Dosing of oseltamivir has been established for infants 2 weeks of age and older.
2.2. Dosing…28-38wk postmenstrual agr :1mg/kg per dose twice daily
2.3. 38-40wk postmenstrual age :1.5mg/kg orally twice daily
2.4. Babies 9-11 mo of age :3.5mg/kg per dose twice daily
3. Interferons targeting viruses
3.1. Cytomegaloviral Infections CMV can result in severe, even fatal disease in immunocompromised patients
3.2. Treatment of immunocompromised with cmv :ganiciclovir 5 mg/kg per dose iv given12 hourly for 2-3 weeks
3.3. Ledipasvir, which is administered in combination with sofosbuvir, blocks the action of an HCV specific protein crucial for viral replication for more than 12 y
